A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy)
Descamps, O. S.; Van Caenegem, O.; Hermans, Michelet al.
Descamps, O. S.; Department of Internal Medicine, Centres Hospitaliers Jolimont, Haine Saint-Paul and Department of Cardiology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Van Caenegem, O.; Department of Cardiology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Hermans, Michel; Department of Endocrinology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Balligand, J.-L.; Department of Internal Medecine, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCL, Bruxelles, Belgium
Beauloye, C.; Department of Cardiology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Bondue, A.; Department of Cardiology and Centre for Human Genetics, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Carlier, S.; Department of Cardiology, Centre Hospitalier Universitaire, Ambroise Paré and Mons University (UMONS), Mons, Belgium
Hoffer, E.; Department of Cardiology, Centre Hospitalier Régional de la Citadelle, Liège, Belgium
Kacenelenbogen, R.; Department of Cardiology, CHU Saint-Pierre and President of the Working Group of Cardiovascular Readaptation and Prevention, Belgium
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Langlois, M.; Department of laboratory Medicine, Algemeen Ziekenhuis Sint-Jan, Brugge, and National Representative of the Royal Belgian Society of Laboratory Medicine, Belgium
Leone, A.; Department of Cardiology, Centre Hospitalier Universitaire de Tivoli La Louvière, Belgium
Mertens, Anne
Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques
Vanakker, O.; Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
Vanoverschelde, J.-L.; Department of Cardiology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Verhaegen, A.; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerpen, Belgium
Vermeersch, P.; Department of laboratory Medicine, Senior Clinical Investigator of the Research Foundation-Flanders (FWO), University Hospital Leuven, The Royal Belgian Society of Laboratory Medicine, Belgium
WALLEMACQ, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Rietzschel, E.; Department of Cardiology, University Hospital Ghent and Ghent University, Belgium
Belgian Atherosclerosis Society/Belgian Lipid Club (BAS/BLC), The Belgian Society Of Cardiology B. S. C. And The Royal Belgian Society Of Laboratory Medicine Rbslm
A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy)
Publication date :
2018
Journal title :
Atherosclerosis
ISSN :
0021-9150
eISSN :
1879-1484
Publisher :
Elsevier Ireland Ltd
Volume :
277
Pages :
369-376
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Abbott Laboratories AstraZeneca Bayer AG Boehringer Ingelheim MSD - Merck Sharp and Dohme Mylan - Mylan Laboratories Pfizer Roche Servier
Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 34:45 (2013), 3478–3490a.
Descamps, O., Hondekijn, J.C., Van Acker, P., Deslypere, J.P., Heller, F.R., High prevalence of a novel mutation in exon 4 in the LDL receptor gene in Belgium. Clin. Genet. 51 (1997), 301–308.
Descamps, O.S., Gilbeau, J.P., Hondekijn, J.C., Leysen, X., Van Leuven, F., Heller, F., Impact of genetic defects on atheroclerosis in patients suspected of familial hypercholesterolemia. Eur. J. Clin. Invest. 31:11 (2001), 958–965.
Descamps, O.S., Gilbeau, J.B., Luwaert, R., Heller, F., Impact of Genetic Defects on coronary atherosclerosis in patients suspected of familial hypercholesterolemia. Eur. J. Clin. Invest. 33 (2003), 1–9.
Descamps, O.S., de Meester, A., Cheron, P., Kastelein, J.J., Heller, F.R., Clinical and preclinical myocardial ischaemia in familial hypercholesterolemia. Atherosclerosis(Supp 4), 2003, 7–8.
Descamps, O.S., Tenoutasse, S., Stephenne, X., Gies, I., Beauloye, V., et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 218:2 (2011), 272–280.
Van Gaal, L.F., Peeters, A.V., De Block, C.E.M., Thiart, R., De Leeuw, I.H., Kotze, M.J., Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolaemics. Mol. Cell. Probes 15 (2001), 329–336.
Sanna, C., Stéphenne, X., Revencu, N., Smets, F., Sassolas, A., Di Filippo, M., Descamps, O.S., Sokal, E.M., Homozygous familial hypercholesterolemia in childhood: genotype-phenotype description, established therapies and perspectives. Atherosclerosis 247 (2016), 97–104.
Vallejo-Vaz, A.J., Kondapally Seshasai, S.R., Cole, D., Hovingh, G.K., Kastelein, J.J., et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 243:1 (2015), 257–259.
De Backer, G., Besseling, J., Chapman, J., Hovingh, G.K., Kastelein, J.J., et al. EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 241:1 (2015), 169–175.
Robinson, J.G., Management of familial hypercholesterolemia: a review of the recommendations from the national lipid association expert panel on familial hypercholesterolemia. J. Manag. Care Pharm. 19:2 (2013), 139–149.
Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS) developed with the special contribution of the european assocciation for cardiovascular prevention & rehabilitation (EACPR). Atherosclerosis 253 (2016), 281–344.
Nordestgaard, B.G., Langsted, A., Mora, S., Kolovou, G., Baum, H., et al. European atherosclerosis society (EAS) and the european federation of clinical chemistry and laboratory medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cutpoints-a joint consensus statement from the european atherosclerosis society and european federation of clinical chemistry and laboratory medicine. Eur. Heart J. 37:25 (2016), 1944–1958.
Jackson, R., Scragg, R., Marshall, R., et al. Changes in serum lipid concentrations during first 24 hours after myocardial infarction. BMJ 294 (1987), 1588–1589.
Wattanasuwan, N., Khan, I.A., Gowda, R.M., Vasavada, B.C., Sacchi, T.J., Effect of acute myocardial infarction on cholesterol ratios. Chest 120:4 (2001), 1196–1199.
Haralambos, K., Whatley, S.D., Edwards, R., Gingell, R., Townsend, D., et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 240:1 (2015), 190–196.
Descamps, O.S., Hondekijn, J.C., Van Leuven, F., Heller, F.R., The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. Atherosclerosis 157 (2001), 514–518.
Harada-Shiba, M., Arai, H., Okamura, T., Yokote, K., Oikawa, S., Nohara, A., Okada, T., Ohta, T., Bujo, H., Watanabe, M., Wakatsuki, A., Yamashita, S., Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J. Atherosclerosis Thromb. 19:11 (2012), 1019–1026.
Kassner, U., Marion Wühle-Demuth, M., Missala, I., Humphries, S.E., et al. Clinical utility gene card for: hyperlipoproteinemia, TYPE II. Eur. J. Hum. Genet., 2014(7), November 2013, 22, 10.1038/ejhg.2013.271 published online 20.
Kastelein, J.J., Ginsberg, H.N., Langslet, G., Hovingh, G.K., Ceska, R., et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36:43 (2015), 2996–3003.
Ginsberg, H.N., Rader, D.J., Raal, F.J., Guyton, J.R., Baccara-Dinet, M.T., et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther. 30:5 (2016), 473–483.
Raal, F.J., Stein, E.A., Dufour, R., Turner, T., Civeira, F., et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:9965 (2015), 331–340.
Gouni-Berthold, I., Descamps, O.S., Fraass, U., Hartfield, E., Allcott, K., et al. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br. J. Clin. Pharmacol. 82:6 (2016), 1412–1443.
Starr, B., Hadfield, S.G., Hutten, B.A., Lansberg, P.J., Leren, T.P., et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 46:6 (2008), 791–803.
Williams, R.R., Hunt, S.C., Schumacher, M.C., Hegele, R.A., Leppert, M.F., Ludwig, E.H., Hopkins, P.N., Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72:2 (1993), 171–176.
Wiegman, A., Gidding, S.S., Watts, G.F., Chapman, M.J., Ginsberg, H.N., et al. For the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J. 36:36 (2015), 2425–2437.
Rietzschel, E.R., De Buyzere, M.L., Bekaert, S., Segers, P., De Bacquer, D., Cooman, L., Van Damme, P., Cassiman, P., Langlois, M., van Oostveldt, P., Verdonck, P., De Backer, G., Gillebert, T.C., Asklepios Investigators. Rationale, design, methods and baseline characteristics of the Asklepios Study. Eur. J. Cardiovasc. Prev. Rehabil. 14:2 (2007), 179–191.
Khera, A.V., Won, H.H., Peloso, G.M., Lawson, K.S., Bartz, T.M., et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67:22 (2016), 2578–2589.